Updates

BIG PHARMA WATCH: NEW STUDY FINDS DRUG COMPANIES CONTINUING TO HIKE PRICES WITHOUT IMPROVING THEIR DRUGS

Jan 13, 2021

Unjustified Rx Price Increases Cost American Patients & Health System Read More

CSRxP STATEMENT ON PCMA LAWSUIT CHALLENGING TRUMP ADMINISTRATION’S REBATE RULE

Jan 12, 2021

Misguided Policy Published in Violation of Legally Required Process for Public Read More

BIG PHARMA WATCH: HEADLINES FROM BIG PHARMA’S NEW YEAR PRICE HIKES

Jan 11, 2021

Second Major Round of Pandemic Price Increases Underscores Urgency for Read More

HAPPY NEW YEAR: BIG PHARMA HIKES PRICES ON MORE THAN 580 RX DRUGS TO START 2021

Jan 4, 2021

Drug Companies Double Down In Second Major Round Of Pandemic Price Hikes As Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 31, 2020

Part IV: Escalating Assault on 340B Program for Providers Serving America’s Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 30, 2020

Part III: Angling to Price-Gouge American Public on COVID-19 Treatments Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 29, 2020

Part II: Gaming the System to Undermine Competition at the Expense of American Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 28, 2020

Part I: Sticking with Price-Hiking “Business-as-Usual” During Pandemic Read More

TWO BIRDS OF A FEATHER: ASTRAZENECA TO ACQUIRE FELLOW PRICE-GOUGER ALEXION IN MULTI-BILLION DOLLAR DEAL

Dec 14, 2020

In case you missed it, Big Pharma giant AstraZeneca announced plans to acquire Read More

CSRXP STATEMENT ON SELECTION OF XAVIER BECERRA FOR THE U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Dec 7, 2020

Campaign Looks Forward to Working with Becerra to Lower Drug Prices Read More

CSRXP: BIG PHARMA MUST BE HELD ACCOUNTABLE FOR ESCALATING ASSAULT ON CRITICAL 340B PROGRAM

Dec 3, 2020

Novo Nordisk Becomes Latest Drug Company to Dodge Requirement to Provide Read More

CSRxP: MISGUIDED REBATE RULE A BIG PHARMA BAILOUT PAID FOR BY AMERICAN SENIORS & TAXPAYERS

Nov 20, 2020

Rebate Rule Will Increase Premiums for Medicare Part D Beneficiaries Read More